References
- Lennert K, Feller A. The Kiel Classification. Histopathology of non-Hodgkin's lymphoma (based on the updated Kiel classification)2nd ed. Springer-Verlag, Berlin, Heidelberg, New York 1992; 13–22
- Lukes R J, Collins R D. Immunologic characterization of human malignant lymphomas. Cancer 1974; 34: 1488–1503
- National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer 1982; 49: 2112–2135
- Harris N, Jaffe E S, Stein H, Banks P M, Chan J KC, Cleary C D, et al. A Revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361–1392
- Kwak L W, Wilson M, Weiss L M, Horning S, Warnke R A, Dorfman R F, et al. Clinical significance of morphologic subdivision in diffuse large cell lymphoma. Cancer 1991; 68: 1988–1993
- Salar A, de Sevilla A F, Romagosa V, Domingo-Claros A, Gonzalez-Barca E, Pera J, et al. Diffuse large B-cell lymphoma: is morphologic subdivision useful in clinical management?. Eur J Haematol 1998; 60: 202–208
- Engelhard M, Brittinger G, Huhn D, Gerhartz H H, Meusers P, Siegert W, et al. Subclassification of Diffuse B-cell Lymphomas according to the Kiel classification: distinction of centroblastic and immunoblastic lymphomas is a significant prognostic risk factor. Blood 1997; 89: 2291–2297
- Baars J W, de Jong D, Willemse E M, Gras L, Dalesio O, v. Heerde P, et al. Diffuse large B-cell lymphomas: the clinical relevance of histological subclassification. Br J Cancer 1999; 79: 1770–1776
- Harris N L, Jaffe E S, Diebold J, Flandrein G, Muller-Hermelink H K, Vardiman T, et al. World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: report of the Clinical Advisory Commitee Meeting – Airlie House, Virginia, November, 1997. J Clin Oncol 1999; 17: 3835–3849
- Diebold J, Anderson J R, Armitage J O, Connors J M, MacLennan K A, Muller-Hermelink H K, et al. Diffuse Large B-cell lymphoma. A clinicopathologic analysis of 444 cases classified according to the updated Kiel classification. Leuk Lymphoma 2002; 43: 97–104
- Colomo L, Lopez-Guillermo A, Perales M, Susana Rives, Martınez A, Bosch F, et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003; 10: 78–83
- De Paepe P, Achten R, Verhoef G, Wlodarska I, Stul M, Vanhentenrijk V, et al. Large cleaved and immunoblastic lymphoma may represent two distinct clinicopathologic entities within the group of diffuse large B-cell Lymphomas. J Clin Oncol 2005; 23: 1–9
- Hans C P, Weisenburger D, Greiner T, Gascoyne R D, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275–282
- Oken M M, Creech R H, Tormey D C, Horton J, Davis T E, McFadden E T, Carbone P P. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649–655